BAFF is involved in macrophage-induced bortezomib resistance in myeloma

Jing Chen, Donghua He, Qingxiao Chen, Xing Guo, Li Yang, Xuanru Lin, Yi Li, Wenjun Wu, Yang Yang, Jingsong He, Enfan Zhang, Qing Yi and Zhen Cai*

We aimed to characterize the role of B-cell activating factor (BAFF) in macrophage-mediated resistance of multiple myeloma (MM) cells to bortezomib (bort), and to further understand the molecular mechanisms involved in the process. First, we detected BAFF and its three receptors on myeloma cells and macrophages using the quantitative reverse transcriptase-polymerase chain reaction and flow cytometry. The secretion of BAFF was tested in patients with MM, MM cell lines, and macrophages. The ability of macrophages to protect MM cells from bort-induced apoptosis was significantly attenuated using BAFF-neutralizing antibody in the co-culture system or knocking down the expression of BAFF in macrophages with small interfering RNA. We also showed that the MM–macrophage interaction through BAFF and its receptors was primarily mediated by the activation of Src, Erk1/2, Akt, and nuclear factor kappa B signaling and the suppression of caspase activation induced by bort. Our data demonstrated that BAFF played a functional role in the macrophage-mediated resistance of MM cells to bort, suggesting that targeting BAFF may provide a basis for the molecular- and immune-targeted therapeutic approach.

Cell Death and Disease (2017) 8, e3161; doi:10.1038/cddis.2017.533; published online 2 November 2017

Multiple myeloma (MM) is a universally clonal B-cell neoplasm characterized by the expansion of malignant plasma cells in the hematopoietic bone marrow (BM). MM cells are protected from both spontaneous and drug-induced apoptosis as a consequence of adhesion to certain microenvironmental components. Bortezomib (bort, Velcade) is one of the best effective treatments for MM. It has simultaneously targeted MM cells and their closely supportive BM environment. Although initial advantages of bort treatment of MM including higher overall response rates are promising, a number of patients develop a resistance to it over time.

To date, the mechanism of bort resistance is unknown. Recent studies have shown that MM cells do manifest a clonal heterogeneity, and their mutation or overexpression of bort-binding protein at the β5 proteasome subunit may result in the acquired resistance to bort. The upregulation of insulin-like growth factor-1, heat shock proteins, β-catenin/Wnt, and c-Met/phosphor c-Met has been suggested. Bort resistance has also been related to the activation of prosurvival autophagy and alterations in bone marrow stromal cells (BMSCs).

Tumor-associated macrophages (MΦs) are the prominent components in the stroma. They provide a favorable microenvironment for tumor cells by cross-talking with other stromal cells and thus promote tumor growth, progression, and metastasis. In MM, MΦs could induce drug resistance by protecting tumor cells from chemotheraphy-induced apoptosis, and microarray analysis has ranked the top 250 paired genes including B-cell activating factor (BAFF) that may play a role in the MΦs–MM cell interaction.

Investigators have reported that myeloma cells express transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA), two genes coding for receptors of BAFF (also known as Blys). BAFF, a member of the tumor necrosis factor (TNF) family, was identified as a key factor in the normal B-cell biology. It also enhances the survival of various B lymphocyte malignancies, including MM. It can act as a membrane-bound or proteolytically cleaved soluble form displaying typical features of type II transmembrane protein. It is expressed predominantly by stromal compartment including osteoclast, MΦs, dendritic cells, and some T cells. Some studies have found that the tumor microenvironment secretes BAFF.

Therefore, we choose to investigate the significance of BAFF in MΦ-mediated MM bort resistance. We showed that primary myeloma cells and MM cell lines expressed BCMA and TACI heterogeneously. The expression of BAFF in MΦs increased compared with monocytes. The BAFF-neutralizing antibody or knockdown of BAFF further attenuated the MΦ-induced bort resistance of MM cells. Thus, we try here to define a key role of BAFF, which is essential for MΦ-mediated bort resistance of MM cells.

Results

Expression of BAFF and its receptors detected in MM cells. Our study first detected the expression of messenger RNA of BAFF and its three receptors, BCMA, TACI, and BAFF-R, from seven patients with MM and in six MM cell lines.
using qRT-PCR to evaluate the relevance of BAFF signaling in MM drug resistance. As shown in Figure 1a, tested primary MM cells express BAFF heterogeneously. Among the receptors of BAFF, the expression of BCMA was significantly higher than that of TACI, with BAFF-R being the lowest: the maximum arbitrary units of BAFF, BCMA, TACI, and BAFF-R were 50, 600, 150, and 5, respectively. Similar results were observed in the six MM cell lines MM.1S, MM.1R, CAG, RPMI8226, ARP-1, and ARK (Figure 1b). Overall, the heterogeneous expression of BAFF and its receptors was consistent with that reported by Yu-Tzu et al.\textsuperscript{18} Then, the surface expression of BAFF and its receptors in the two MM cell lines ARP-1 and RPMI8226 was examined using flow cytometry. Notably, ARP-1 and RPMI8226 expressed higher levels of BCMA and TACI, lower levels of BAFF, and virtually undetectable BAFF-R, suggesting that altered expression of BAFF and its receptors might contribute to the process of MM cells resistant to apoptosis.

### PBMC-induced MΦs and expression of BAFF and its receptors in MΦs

Macrophage colony-stimulating factor (M-CSF) is a key homeostatic growth factor involved in the maintenance and differentiation of MΦs.\textsuperscript{15} It is well established that M-CSF preferentially stimulated M2-like MΦ phenotypes.\textsuperscript{20–23} M2-like MΦs had characteristics of spindle-like cells and relatively high expression of CD163 surface marker.\textsuperscript{24} In our study, MΦs were harvested from peripheral blood monocytes (PBMCs) of healthy donors, which were incubated for 7 days with M-CSF. We observed that the cultured MΦs were adherent to the six-well plates and had a spindle-like morphology (Figure 2a). The expression of CD68 and CD163 of MΦs from different donors was (24.6 ± 0.39%) and (78.4 ± 0.67%), respectively. The flow cytometry analysis of the two CD molecules in MΦs is shown in Figure 2b. Simultaneously, the expression of BAFF was measured during MΦ differentiation. As shown in Figure 2c, MΦ had increased expression of BAFF compared with monocytes (\(P<0.05\)), and in monocyte-derived MΦ, BAFF had relatively high expression whereas its receptors were barely detected by flow cytometry (Figure 2d). We also identified the expression of BAFF in CD68+ monocytes/MΦs from BM aspirates of patients with MM using

---

**Figure 1** Expression of BAFF and BAFF-Rs in myeloma cells. The mRNA expression of BAFF and its receptors (BAFF-R, TACI, and BCMA) were detected using RT-PCR in seven CD138+ purified primary MM cell samples (a) and in six MM cell lines MM.1S, MM.1R, CAG, RPMI8226, ARP-1, and ARK (b). The cell surface expression of BAFF and its receptors in ARP-1 and RPMI8226 were detected by flow cytometry using anti-BAFF, anti-BAFF-R, anti-TACI, and anti-BCMA (blue lines) for 15 min at room temperature. Red lines indicate isotype Ig controls, done for each sample (c)
Figure 2  PBMC-induced MΦs and the expression of BAFF and BAFF-Rs in MΦs. Monocytes from healthy donors were cultured in RPMI-1640 supplemented with 10% FBS in the presence of M-CSF (10 ng/ml) for 7 days. (a) M2-type MΦs adhered to the six-well plates and had a spindle-like morphology. (b) MΦs were positive for CD68 and CD163 by flow cytometry analysis. (c) Monocytes and monocyte-induced MΦs from seven blood donors were detected for the expression of BAFF by the flow cytometry analysis. Numbers represent the mean fluorescent intensity. (d) Cell surface expression of BAFF and its receptors in MΦs were detected by flow cytometry. (e) Expression of BAFF on primary MΦs from BM aspirates of patients with MM (n=2) were detected using immunofluorescence. (f) Expression of BAFF on monocyte-derived osteoclast, monocytes, MΦs, polynuclear cells, bone marrow monocytes were detected by Western blot.

Figure 3  Expression of soluble BAFF. The supernatants of (a) BM of 27 patients with MM and (b) MM cell lines, osteoclasts, monocytes, MΦs and polynuclear cells from six donors were collected for detecting BAFF using ELISA.
immunofluorescence (Figure 2e). Moreaux et al. had pointed out BAFF were mainly expressed by osteoclasts and BMSCs in the bone microenvironment. Concerning the induction of MΦs in our experiment, we simultaneously detected BAFF expression in monocyte-derived osteoclast, monocytes, MΦs, polynuclear cells, BM monocytes by western blot. Of major interest, MΦs largely expressed BAFF while osteoclasts weekly expressed BAFF (Figure 2f).

**BAFF production by BM cells, MM cell lines, and MΦs.** As BAFF is a secreted protein, we explored the presence of BAFF protein in the supernatants of BM of patients with MM, MM cell lines, and osteoclasts, monocytes, MΦs, polynuclear cells, BM monocytes by various donors. Using ELISA, soluble BAFF levels were 1306.9, 20.5, 41.7, 9.60, 80.7, and 29.7 pg/ml in culture supernatants of BM of patients with MM, MM cell lines, osteoclasts, monocytes, MΦs and polynuclear cells, respectively, showing the presence of the soluble form of BAFF (Figures 3a and b).

**PBMC-induced MΦs were insensitive to bort and protected MM cells from bort-induced apoptosis.** Because BM microenvironment contributes to the drug resistance of plasma cells, we wondered whether MΦs mediated the resistance of MM cells to bort. The role of PBMC-derived MΦs in vitro was determined via bort-induced apoptosis of ARP-1, RPMI8226, and CD138+ plasma cells from patients with MM. We first investigated the direct function of bort on MΦs. Bort (range 0–80 nM) had small effect in inducing apoptosis of MΦs (Figure 4a). Besides, MΦs co-cultured with ARP-1 (bort, 5 nM) and RPMI8226 (bort, 10 nM) significantly weakened bort-induced apoptosis (Figures 4b and c). Bort concentration was determined according to the inhibitory concentration 50% of ARP-1 and RPMI8226 (data not shown). Moreover, CD138+ plasma cells from four patients with MM, which were susceptible to spontaneous apoptosis in vitro, were obviously protected by MΦs (Figure 4d) when co-cultured with MΦs, suggesting the protective effect of MΦs. We also extended our study to the conventional agent melphalan (Mel) and histone deacetylase inhibitors (HDACi) panobinostat (Pano). The results showed that MΦs protected ARP-1 and RPMI8226 from Mel-induced apoptosis under the co-culture condition. However, the protective effect was no longer observed when tested MM cells were treated with Pano (Figures 4e and f).

**BAFF was indispensable for MΦ-mediated bort resistance of MM cells.** A previous study provided the gene expression profile data of MM cells and MΦs cultured alone or co-cultured, 250 paired genes were differentially expressed. Based on these data, we hypothesized that BAFF (on MΦs) and its receptors (on MM cells) played a role in the MΦ-mediated bort resistance of MM cells. MΦs were cultured alone or co-cultured with MM cell lines for 24 h, the suspended MM cells were removed and washed with phosphate-buffered saline (PBS) to obtain pure MΦs, we found MΦs in co-cultured condition led to an increased expression of BAFF as detected by western blot (Figure 5a). We interrupted the interaction between BAFF and its receptors using BAFF-neutralizing antibody, and then examined MΦ-mediated protection. As shown in Figures 5b and c, the BAFF-neutralizing antibody, but not control IgG2B, repressed the MΦ-mediated bort resistance of MM cells (ARP-1 and RPMI8226) and partially restored MM cell sensitivity to bort in direct co-culture with MΦs. Similar findings are shown in Figure 5d in which BAFF-neutralizing antibody attenuated the MΦ-mediated spontaneous apoptosis of CD138+ plasma cells compared with control IgG2B. We also examined MΦ-mediated MM drug resistance in BAFF-knocked down MΦs. MΦs were transduced with siRNAs targeting BAFF (TNSF13B-Homo-296, TNSF13B-Homo-700, and TNSF13B-Homo-973) or control nontargeting siRNA. The transduction of BAFF-specific siRNAs reduced protein levels of BAFF in MΦs differently (Figure 5e). TNSF13B-Homo-973 confirmed that significant BAFF knockdown resulted in the reduced ability of MΦs in protecting MM cells (ARP-1 and RPMI8226) from bort-induced apoptosis (Figures 5f and g; compared with siCt-MΦs). Thus, our findings indicated that BAFF (on MΦs) and its receptors (on MM cells) played a profound role in MΦ-mediated bort resistance of MM cells. Similarly, BAFF-knocked down MΦs were not protecting MM cells against Mel-induced apoptosis to a large extent (Supplementary Figures 1A and B).

**Effect of BAFF on signaling pathway in co-cultured MM cells.** To learn if the intracellular survival signaling was stimulated by MΦ/MM co-culture that conferred bort resistance of MM cells in vitro, first, apoptotic cell characteristics of PARP and caspase-3 cleavage were detected using western blot in MM cells under co-culture conditions either with BAFF-neutralizing antibody or control IgG2B in the presence of bort. The result showed that in ARP-1 cells co-cultured with MΦs, bort-induced PARP and caspase-3 cleavage had high repression (Figure 6a). However, neutralization of BAFF under co-culture conditions or ARP-1 cells co-cultured with BAFF-knocked MΦs (Supplementary Figure 2A) had moderate elevation of these apoptotic proteins (Figure 6b). Next, the possible signaling mediators were examined in MM cells.
MØs were found to activate phosphorylated Akt, Erk1/2 kinase, and Src in ARP-1 cells treated with bort, which had lower levels of p-Akt, p-Erk1/2, and p-Src when treated with BAFF-neutralizing antibody. Similar findings were also observed from BAFF-knocked-down MØs (Supplementary Figure 2B) co-cultured with ARP-1 cells, suggesting that BAFF played a role in MØ-mediated bort resistance through Akt, Erk1/2 and Src pathway activation (Figure 6c).

A previous study explained that the BAFF promoter was an essential activation element of nuclear factor kappa B (NF-κB) transcription triggered by the adhesion of MM cells to BMSCs.26 NF-κB activation relies on both NIK (NF-κB-inducing kinase) and its downstream kinase IKKα with the persistent degradation of TRAF3 and increased expression of NIK. It also involves the processing of p100 to p52 and translocation of p52 to the nuclear fraction.27–29 Our present study found that BAFF-knocked-down MØs (Supplementary Figure 2C) co-cultured with ARP-1 cells partly repressed the activation of NF-κB (Figure 6d). We also observed the degradation and phosphorylation of the inhibitor of kappa Bα (IκBα) and p65 translocation to the nucleus, implying the activation of the canonical pathway of NF-κB (Figures 6d and e). The signaling pathway was not activated further by co-culture with BAFF-knocked-down MØs (Figures 6d and e). These results indicated that BAFF-induced bort resistance of MM cells co-cultured with MØs was conducted via activation of both classical and alternative NF-κB pathways.

**MØ-mediated bort resistance of MM cells in vivo.** The human MM-NOD-SCID mouse model was used to evaluate whether in vivo environment corresponded to in vitro findings that MØs could protect myeloma cells from bort-induced apoptosis. ARP-1 cells and ARP-1 mixed with monocytes were subcutaneously injected into the flanks of NOD-SCID mice. We enumerated MØ infiltration in a tumor by immunohistochemical analysis using the anti-human CD68 antibody (Figure 7a). Mice bearing ARP-1 tumor alone or ARP-1 tumor mixed with human MØs were treated with bort every 3 days to assess bort-induced cell death in vivo. After treatment for 2 consecutive weeks, the mice were killed and the tumors were harvested. Then, the apoptotic cells of tumor masses were detected by immunohistochemistry staining with the anti-cPARP antibody (Figure 7b) and flow cytometry analyses for Annexin V-FITC/propidium iodide(Pi)-positive cells (Figure 7c). The tumor generated by ARP-1 alone cells had more positive staining of cPARP and Annexin V/Pi. These results supported that MØs could protect MM cells in the presence of bort in vivo. Consistently, this study found that mice bearing ARP-1/MØ cells had a larger tumor volume in the presence and absence of bort (Figure 7d), indicating that MØs manifested compromised therapeutic effects of bort (a 2-week treatment schedule) on tumors. Furthermore, we observed in vivo tumors from BAFF-neutralizing antibody-treated ARP-1/MØ mice, which showed small-sized volumes compared with control IgG2B-treated group with bort as described earlier (Figures 7e and f). These results are correspondent with in vitro studies showing that BAFF was involved in MØ-mediated bort resistance of MM cells.

**Discussion**

Mechanisms of bort resistance in MM have been implicated in both intrinsic changes, including MM cells and their subclone heterogeneity, and the protective efficacy of BMSCs.6,7,30 We demonstrated that primary CD138+ plasma cells from patients with MM underwent spontaneous apoptosis in vitro, suggesting that plasma cells in vivo reacquired susceptibility when separated from the BM microenvironment in vitro. MØs, a type of BMSCs, were heavily infiltrated in the myeloma microenvironment.31,32 The specific roles of MØs in the pathogenesis of tumors are now being delineated. For example, a previous study demonstrated that MØs exhibited tumor-promoting activities via increasing angiogenesis and metastasis, and suppressing anti-tumor immunity.33,34 In particular MØs could mediate multidrug resistance of MM cells to both conventional and novel chemotherapy drugs.10 Our present study demonstrated that PBMC-induced MØs were resistant to bort in vitro and protected primary MM cells and MM cell lines from spontaneous and bort-induced apoptosis. Of note, we found MØs were not able to reduce panobinostat-induced MM apoptosis. Histone deacetylase inhibitor panobinostat has emerged as a particular treatment option for MM. Previous studies showed the anti-myeloma activity of panobinostat was related to changes in intracellular modifications that influence the interaction of MM cells with the microenvironment.35 The positive alteration of panobinostat to MM microenvironment which comprises extracellular matrix and the BMSC may account for the disappeared protective effect of MØs. We thus assume defining the mechanisms whereby MØs protected MM cells could potentially identify a promising target for MM therapy.

BAFF, a member of the TNF superfamily, was identified as a humoral factor highly expressed in the BM microenvironment of MM. Studies showed that BMSCs were the main product source of BAFF.13,18 Because myeloid lineage cell monocytes including MØs, dendritic cells were originally found to express BAFF in myeloma
J Chen et al

Cell Death and Disease

**Figure 5** BAFF is indispensable for MØ-mediated MM bort resistance. (a) Lysates from MØs either cultured alone or co-cultured with MM cell lines (ARP-1 and RPMI8226) were detected for the expression of BAFF protein using an anti-BAFF antibody by Western blot, with GAPDH used as a loading control. Apoptosis was evaluated by flow cytometry with Annexin V-FITC/propidium iodide staining. (b) A representative result showing the percentage of bort-induced apoptotic MM cells (5 nM ARP-1 and 10 nM RPMI8226) in direct co-culture with MØs, in the presence of BAFF-neutralizing antibody (20 μg/ml) or control IgG2B (20 μg/ml). (c) Reduced protective effect of MØs in the presence of BAFF-neutralizing antibody is analyzed as means ± S.D. (d) Results showing BAFF-neutralizing antibody attenuated the effect of MØs in protecting primary CD138+ plasma cells from spontaneous apoptosis. Values are presented as means ± S.D. (e) MØs treated with BAFF-specific siRNAs showed a diverse reduction of BAFF protein compared with nontargeting siRNA (control) at 72 h using Western blot, with GAPDH as a loading control. (f) A representative result showing bort-induced apoptosis on ARP-1 cells co-cultured with MØs following the BAFF-specific siRNAs using flow cytometry analysis. The BAFF knockdown effect resulted in reduced ability of MØs in protecting MM cells. (g) Result showing percentage of bort-induced apoptotic MM cells (ARP-1 and RPMI8226) in direct co-culture with BAFF-knocked down MØs. Values are presented as means ± S.D.* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
**Figure 6** Involvement of BAFF in MΦ-mediated protection of ARP-1 cells. Western blot analyses showed that (a) ARP-1 cells cultured alone or co-cultured in direct contact with MΦs were detected for activation and cleavage of PARP and caspase-3, either PBS-treated or bort-treated (5 nM, 24 h). (b) ARP-1 cells cultured alone or co-cultured in direct contact with sictl-MΦs or siBAFF-MΦs were detected for activation and cleavage of PARP and caspase-3, either PBS-treated or bort-treated (5 nM, 24 h). (c) Expression of pAkt (Ser473), Akt, pErk1/2 (T202/Y204), Erk, pSrc (Y416), Src, and GAPDH in ARP-1 cells cultured alone or co-cultured with MΦs in the presence of BAFF-neutralizing antibody or control IgG2B and in ARP-1 cells cultured alone or co-cultured with sictl-MΦs or siBAFF-MΦs, either PBS-treated or bort-treated (5 nM, 24 h). (d) Expression of TRAF3, NIK, IkBα, and pIkBa (Ser32) in ARP-1 cells directly co-cultured with sictl-MΦs or siBAFF-MΦs, either PBS-treated or bort-treated (5 nM, 24 h). (e) Processing of p100 to p52 and translocation of p52 or p65 to the nucleus in ARP-1 cells directly co-cultured with sictl-MΦs or siBAFF-MΦs, bort-treated (5 nM, 24 h).
Figure 7. In vivo effect of MΦ-mediated MM bort resistance in the myeloma NOD−SCID mouse model. (a) Human MΦ infiltration in tumors from ARP-1 cells (ARP-1 only tumor) and ARP-1/monocytes (ARP-1/MΦ tumor) was detected by immunohistochemistry staining of CD68. Tumors from myeloma-bearing NOD−SCID mice treated with bort (2 μg/mouse every 3 days for 2 consecutive weeks) or PBS (served as controls) were detected for apoptotic cells (b) using immunohistochemistry staining with anti-cPARP antibody and (c) flow cytometry staining with Annexin V-FITC/propidium iodide. (d) Tumor burdens under different groups were detected as tumor volume. (e) Tumor volume of bort-treated myeloma-bearing NOD−SCID mice (n = 5/group) treated with BAFF-neutralizing antibody (100 mg/mouse, every 3 days for 2 consecutive weeks) or control IgG2B. *P<0.05. (f) Tumor volume in different treatment groups.
BAFF and MΦs are important components of the BMSCs of MM that support plasma cell survival and induce chemotherapy resistance. Therefore, we anticipated a role of BAFF in the adhesion of MΦs and MM cells. Our study demonstrated that MΦs had increased expression of BAFF compared with monocytes, and the secretion level of BAFF in MΦs was higher than that in MM cell lines, which was in accordance with previous reports that BAFF signaling acted mainly through a paracrine system rather than an autocrine mechanism. We also demonstrated that PBMC-induced MΦs could protect MM cells from both spontaneous and bort-induced apoptosis. When we utilized BAFF-neutralizing antibody under co-culture conditions or knocked-down expression of BAFF on MΦs, MM cell apoptosis significantly increased, implying that BAFF on MΦs could contribute to their ability to confer MM cells with resistance to bort. Therefore, strategies that interfere with BAFF only might be useful to attenuate the resistance of MM cells to bort in vivo.

Our data showed that MΦs mediated bort resistance of MM cells, suggesting that the mechanism might be associated with the survival signaling pathway activation of MM cells. Indeed, the present study detected the activation of phosphorylated Akt, Erk1/2 kinase and Src in MM cell lines following co-culture with MΦs, all of which were essential to promote MM cell growth and drug resistance. We also identified that the survival pathway activation was attenuated when the expression of BAFF was interrupted in the co-culture system. Thus, it is plausible that BAFF supports the development of bort resistance of MM cells.

BAFF triggers its functions through NF-κB activation, and two main pathways (canonical and alternative) modulate the activity of NF-κB. The canonical pathway activation results from the degradation of IκB and thus leads to the nuclear translocation of p65. Activation of the alternative pathway results from IKKα-dependent p100 phosphorylation and nuclear translocation of p52. The present study showed that BAFF-induced bort resistance of MM cells/MΦs took place via activation of both classical and alternative NF-κB pathways. This is similar to the interaction between BAFF and its receptors on lymphoma and normal B cells, which promotes IκB degradation and processes of NF-κB2, respectively.

Monoclonal antibody-based therapies existed great promise in MM. Recently, tabalumab (LY2127399), with neutralizing activity against BAFF, was found to be well tolerated and showed a better response when combined with bort in relapsed and refractory patients with MM. Indeed there are other molecules such as APRIL, BAFF-R, BCMA, and TACI related to BAFF signaling pathway, and particularly APRIL is evidenced playing significant role in MM cell survival and targeting BCMA is in development. Despite these complexities, it remains crucial to examine whether targeting BAFF alone in MM is sufficient, and the overall results highlighted a functional role of BAFF in MΦ-mediated bort resistance of MM cells, providing a basis for the molecular- and immune-targeted therapeutic approach. Taken together, BAFF signaling might serve as an interesting target for MM treatment.

Materials and Methods

Cell preparation and culture. Human MM cell lines MM.1S, MM.1R, CAG, RPMI8226, ARP-1, and ARK were generously provided by Dr. Qing Yi (Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA). All MM cell lines expressed CD138 (>97% of cells) as detected by the flow cytometric analysis. BM samples were obtained from patients with MM after informed consent from all patients and the approval of the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. Freshly isolated CD138+ cells were purified by positive selection using CD138 microbeads (Miltenyi Biotech, San Diego, CA, USA). All MM cell lines and primary MM cells were maintained in the RPMI-1640 medium containing l-glutamine (Corning Cello, Tewksbury, MA, USA), supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Gibco, Waltham, MA, USA), at 37°C and in 5% CO2 in air.

PBMCs were obtained from healthy donors after informed consent. Human MΦs were generated from PBMCs in vitro as described in a previous study. Monocytes were cultured at 12–18 million per six-well plates in the RPMI-1640 medium. After 1–2 h of incubation, nonadherent cells were removed and adherent monocytes were cultured in RPMI-1640 containing 10% FBS and M-CSF (10 mg/ml; R&D systems, Minneapolis, MN, USA) for 7 days to transform into MΦs. Before use, MΦs were phenotyped by morphological and detected for classic molecular markers CD68 and CD163.

The MM cells were directly added to MΦs at a 1:1 ratio and co-cultured for 24 h with bort to evaluate the effect of MΦs on bort-induced apoptosis in MM cells. Suspended MM cells were obtained by collecting the supernatant and then tested via flow cytometric analysis.

Reagents. Primary antibodies against caspase-3, poly(APD-ribos) polymerase 1 (PARP-1), Akt, phospho-Akt (Ser473), phospho-Akt (Ser308), Src, pSrc (Y416), Erk, pErk (T202/204), and CD68 were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-CD138 was from Abcam (Cambridge, UK). APC anti-human CD68, PE mouse anti-human CD163, PE mouse anti-human BAFF, APC rat anti-human CD267 (TACI), PE anti-human CD269 (BCMA), and fluorescein isothiocyanate (FITC) mouse anti-human CD268 (BAFF receptor, or BAFF-R) were all obtained from Biolegend (San Diego, CA, USA). Primary antibodies including β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from Sigma-Aldrich (Billerica, MA, USA). Horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse antibodies were procured from Jackson Immunoresearch Laboratories (Lancaster, PA, USA). Human BAFF antibody and mouse immunoglobulin G2b (IgG2b) isotype control were purchased from R&D Systems.

RNA extraction and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis. The total RNA from MM cells was extracted using a Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA). qRT-PCR was performed using the Taq universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) with the Bio-Rad CFX96 real-time system, according to the manufacturer’s instruction, and normalized to GAPDH RNA levels calculated by the 2-ΔΔCt method. The sensitivity of the kit was 6.44 pg/ml.

Cell proliferation assay. Cell growth was assessed using a Cell Counting Kit-8 (CCK-8) proliferation assay (Dojindo, Kumamoto, Japan). Cells (5 × 103/100 μl per well) cultured in 96-well plates at indicated times were incubated with CCK-8 for the last 2 h. Then the absorbance was measured at 450 nm using a microplate reader (Bio-Rad, Model 680).

Enzyme-linked immunosorbent assay. MM cells and MΦs (3 × 105/ml) were cultured alone in six-well plates for 48 h. The supernatants harvested from 48 h cultures and those of BM of 27 patients with MM were measured for soluble BAFF using the Human BAFF/Bly/STNFSF13B Quantikine enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems), according to the manufacturer’s instruction. The sensitivity of the kit was 6.44 pg/ml.
Flow cytometry: cell surface antigens and apoptosis. The expression of BAFF, BCMA, TACI, BAFF-R, CD68, CD163, and CD138 was measured by direct immunofluorescence using APC-conjugated CD68, CD138, TACI, PE-conjugated CD163, BAFF, BCMA; and FITC-conjugated BAFF-R. Each isotype control was determined to exclude the possibility of nonspecific influence. After staining, the cells were washed twice and then suspended in PBS and analyzed using a FACSscan flow cytometer (BD Biosciences, San Diego, CA, USA).

The apoptotic cells were measured by staining cells using Annexin V-binding buffer (PharMingen, San Diego, CA, USA), along with Annexin V-FITC/propridium iodide, following the manufacturer’s instructions. After incubating for 10 min at room temperature, the samples were detected by flow cytometry and apoptotic cells were analyzed using FlowJo 7.6.1.

Western blot analysis. The cells were harvested, washed twice with PBS, and extracted using the lysis buffer containing a mixture of protease and phosphatase inhibitor (Thermo Fisher Scientific). The suspension was incubated for 30–60 min at 4 °C, then centrifuged at 16 000 r.p.m. for 30 min at 4 ºC. The supernatant was then used as whole-cell lysates. The protein concentration was determined using the Bio-Rad Protein Assay. The samples were boiled at 95 ºC for 5 min after mixing with a 4 x sodium dodecyl sulfate (SDS) loading buffer (Invitrogen). The proteins (20–40 µg) were separated on 15% SDS-polyacrylamide gel electrophoresis and subsequently transferred to a polyvinylidene difluoride membrane (Merck Millipore, Darmstadt, Germany). The membranes were blocked with 5% bovine serum albumin for 1–2 h at room temperature. Then, the blots were incubated with primary antibodies overnight at 4 ºC. Immunoblots were washed with Tris-buffered saline with Tween (TBST) buffer three times and incubated with HRP-conjugated anti-mouse or anti-rabbit antibodies (1:5000) for 1 h at room temperature, followed by TBST washing three times and subsequent autoradiography with the ChemiDoc MP Imaging System (Bio-Rad) using an enhanced chemiluminescence detection kit (Biological Industries Israel Beit Haemek Ltd., Kibbutz Beit Hamek, Israel).

RNA interference. PBMC-induced Mφs were transiently transfected with three siRNAs (TNSF13B-Homo-296-5′-GCCGCUUACUCUUGGUCAUUTT-3′; TNSF13B-Homo-700-5′-CUGCUUUCACUGAUUGCAT-3′; TNSF13B-Homo-973-5′-GCCGUAACACAUCCCAUUTT-3′) against human BAFF (TNFSF13B) and a scrambled nond bestselling siRNA (GenePharm, Shanghai, China) using Lip2000 (Life Technology, Pittsburgh, PA, USA). The BAFF-specific siRNA-transfected Mφs were co-cultured with MM cells with or without bort, and then evaluated in functional studies.

Immunofluorescence and immunohistochemistry analyses. Paraformaldehyde-fixed, Triton X-100 permeabilized cells of the BM biopsy tissues from patients with MM were used for immunofluorescence staining to analyze the expression of BAFF in CD68-expressing Mφs. Also, paraformaldehyde-fixed paraffin-embedded sections (5 µm) of tumor tissues from tumor-bearing NOD-SCID (nonobese diabetic-severe combined immunodeficient) mice were used for immunohistochemistry staining to analyze CD68-expressing Mφs and cleaved PARP (apoptotic tumor cells) as described earlier.44

Mφ-mediated bort resistance of MM cells in vivo. Four-week-old female NOD-SCID mice were obtained from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China) and housed in the animal facility of Zhejiang University School of Medicine. The Tab of Animal Experimental Ethical Inspection of the First Affiliated Hospital, College of Medicine, Zhejiang University approved the procedures and protocols of all experiments. The mice were subcutaneously injected in the right flank with one million ARP-1 (control group) and one million ARP-1/half million monocyes both suspended in 100 µl of PBS. After palpable tumors (tumor diameter ≥ 5 mm) developed, they were harvested for immunohistochemistry staining of CD68 to determine the infiltration of Mφs. Some mice received intraperitoneal injections of bort (2 mg/mouse, every 3 days) for 2 weeks, and injections of PBS served as a control. In some experiments, the mice received intraperitoneal injections of BAFF-neutralizing antibody or control IgG2b (100 mg/mouse, every 3 days), and administered with bort as described earlier. Tumor sizes were measured every 3 days using calipers and calculated using the formula V = 1/2 (length x width³).

Statistical analysis. Data were analyzed using the GraphPad Prism 6 (GraphPad Software, LaJolla, CA, USA) and Microsoft Office Excel. All results were expressed as mean ± standard deviation (S.D.), and the statistical differences among two groups were determined using a two-tailed Student’s t-test. All P-values < 0.05 were recognized as statistically significant. All experiments were performed in triplicate and three or more independent assays. *P<0.05. **P<0.01, ***P<0.001.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This work was supported by National Natural Science Foundation of China (Project No. 31371380, No. 81201868, No. 91429302). We appreciate all staff from Zhejiang University School of Medicine and thank professor Qing Yi for guiding the experiments.

Author contributions
DH and ZC initiated the study, designed the experiment, JC and DH performed the majority of the experiments, JC wrote the manuscript. QC, LY, XG, XL and YL performed the research, analyzed the data. WW, YY and EZ collected primary samples for the study. JH, QY, ZC supervised experiments.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

BAFF in myeloma
J Chen et al.

1. Voitou E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzoues C et al. RECO1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia 2017; 31: 2104–2113.
2. Fairfield H, Falnik C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann NY Acad Sci 2016; 1364: 32–51.
3. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J clin oncol 2005; 23: 630–639.
4. Anderson KC. Progress and paradigms in multiple myeloma. Clin cancer res 2016; 22: 5419–5427.
5. Bar-Natan M, Stropinsky D, Luptakova K, Coll MD, Apel A, Rajabi H et al. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J haematol 2017.
6. Loh JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer cell 2014; 25: 91–101.
7. Ruschak AM, Sissai M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007–1017.
8. Prasadant MA, De Verman K, Desantis V, Di Marzo V, Vergara D, Ruggieri S et al. Halting pro-survival autophagy by TGFbeta inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia 2016; 30: 640–648.
9. AbdI J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 2013; 4: 2186–2207.
10. Zhong Y, Yang J, Qian J, Qi P, Hanabuchi S, Lu Y et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in multiple myeloma. Leukemia 2013; 27: 702–710.
11. Moreaux J, Legouffe E, Jourdan E, Quettet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3149–3157.
12. Neri P, Kumar S, Fulciniti MT, Valet S, Chhetri S, Mukherjee S et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin cancer res 2007; 13: 5903–5909.
13. Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood cancer J 2015; 5: e282.
14. Raje NS, Moreau P, Terpos E, Bensoubre L, Grzasko N, Holstein SA et al. Phase II study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J haematol 2016; 176: 783–795.
15. Vincent FB, Saulep-Easton D, Figgatt WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine growth factor rev 2013; 24: 203–215.
16. Raje NS, Faber EA Jr., Richardson PG, Schiller G, Hoit RJ, Cohen AD et al. Phase I study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Clin cancer res 2016; 22: 5686–5695.
17. Moreaux J, Cremers FW, Remes T, Raab M, Mahboubi K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021–1030.

18. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. J Immunol 2012; 188: 6365–6374.

19. Montano Almendras CP, Thudium CS, Lofvall H, Moscatelli I, Schambach A, Henriksen K et al. Forced expression of human B-CSF in CD34+ cells promotes monocyte differentiation in vitro and in vivo but blunts osteoclastogenesis in vitro. Eur J haematol 2017; 98: 517–526.

20. Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generating and M-CSF-dependent macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol 2013; 281: 51–61.

21. Mia S, Warnecke A, Zhang XM, Malmstrom V, Harris RA. An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/G-CSF-beta yields a dominant immunosuppressive phenotype. Scand J Immunol 2014; 79: 305–314.

22. Sierra-Filardi E, Nieto C, Dominguez-Soto A, Barroso R, Sanchez-Mateos P, Puig-Kroger A et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol 2014; 192: 3858–3867.

23. Na VR, Hong JH, Lee MY, Jung JH, Jung D, Kim YW et al. Proteomic analysis reveals distinct metabolic differences between granulocyte-macrophage colony stimulating factor (GM-CSF) and macrophage colony stimulating factor (M-CSF) grown macrophages derived from murine bone marrow cells. Mol cell proteom 2015; 14: 2722–2732.

24. Osman A, Bhuwan F, Hashimoto M, Nasser H, Maekawa T, Suzu S. M-CSF inhibits anti-HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages. J Immunol 2014; 192: 5083–5089.

25. Wang J, Hendrix A, Herot S, Lemaire M, De Bryne E, Van Valckenborgh E et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 2014; 124: 556–566.

26. Bolkun L, LemanecWicz D, Jablonska E, Kuczkow J et al. Proteomic analysis reveals drug-induced apoptosis. Blood 2014; 124: 3076–3088.

27. Demchenko YN, Brents LA, Li Z, Bergsagel LP, McGee LR, Kuehl MW. Novel inhibitors are cytotoxic for myeloma cells with NRFB inducing kinase-dependent activation of NRFB. Oncotarget 2014; 5: 4564–4566.

28. Gough S, Dass JF. Signaling of pathway cross-talk interactions with NF-kappaB leading to its activation via ubiquitination or phosphorylation: A brief review. Gene 2016; 584: 97–109.

29. Demchenko YN, Kuehl WM. A critical role for the NRFB pathway in multiple myeloma. Oncotarget 2010; 1: 59–68.

30. Hidashita T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer res 2001; 61: 3071–3076.

31. Zheng Y, Cai Z, Wang S, Zhang X, Gian J, Hong S et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy via APRIL expression. Blood 2009; 114: 3625–3628.

32. Gutierrez-Gonzalez A, Martinez-Moreno M, Samaniego R, Arellano-Sanchez N, Salinas-Munoz L, Relloso M et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood 2016; 128: 2241–2252.

33. Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connelly EM, Li J et al. Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer immunol res 2017; 5: 17–28.

34. Caux C, Ramos RN, Prendergast GC, Bendsris-Vermare N, Menetrier-Caux C. A milestone review on how macrophages affect tumor growth. Cancer res 2016; 76: 6439–6442.

35. Chhabra S. Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics. Pharmaceuticals 2017; 10: (doi:10.3390/ph10020040).

36. Moore PA, Belvedere O, Orr A, Peri L, Lefleur DW, Feng P et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260–263.

37. Cramton A, Magsalett D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003; 101: 4464–4471.

38. Karin M, Cao Y, Goren FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301–310.

39. Mackay F, Figgett WA, Saulie P, Lepege M, Hibbs ML. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol rev 2010; 237: 205–225.

40. Yang S, Li JY, Xu W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit rev onco/hematol 2014; 91: 113–122.

41. Su T, Li J, Meng M, Zhao S, Xu Y, Ding X et al. Bone marrow stromal cells induced activation of nuclear factor kappaB signaling protects non-Hodgkin's B lymphoma cells from apoptosis. Tumour Biol 2016; 37: 10745–10752.

42. Kuo SH, Tsai HJ, Lin CW, Yeh KH, Lee HW, Wei MF et al. The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21). J Pathol 2017; 241: 420–433.

43. Raje N, Longo DL. Monoclonal antibodies in multiple myeloma come of age. N Engl J med 2015; 373: 1264–1266.

44. Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in vivo and in vivo xenograft models. Cancer Lett 2015; 356: 443–453.